Universitat de Lleida
    • English
    • català
    • español
  • español 
    • English
    • català
    • español
  • Iniciar sesión
Repositori Obert UdL
Ver ítem 
  •   Inicio
  • Recerca
  • Medicina
  • Articles publicats (Medicina)
  • Ver ítem
  •   Inicio
  • Recerca
  • Medicina
  • Articles publicats (Medicina)
  • Ver ítem
JavaScript is disabled for your browser. Some features of this site may not work without it.

Liraglutide Improves Forced Vital Capacity in Individuals With Type 2 Diabetes: Data From the Randomized Crossover LIRALUNG Study

Thumbnail
Ver/Abrir
031771.pdf (603.3Kb)
Fecha de publicación
2022
Autor/a
López Cano, Carolina
Ciudin, Andreea
Sánchez Peña, Enric
Tinahones, Francisco José
Barbé Illa, Ferran
Dalmases, Mireia
García Ramírez, Marta
Soto, Alfonso
Michela Gaeta, Anna
Pellitero, Silvia
Martí, Raquel
Hernández, Cristina
Simó, Rafael
Lecube Torelló, Albert
Cita recomendada
López Cano, Carolina; Ciudin, Andreea; Sánchez Peña, Enric; Tinahones, Francisco José; Barbé Illa, Ferran; Dalmases, Mireia; ... Lecube Torelló, Albert. (2022) . Liraglutide Improves Forced Vital Capacity in Individuals With Type 2 Diabetes: Data From the Randomized Crossover LIRALUNG Study. Diabetes 2022, vol. 71, núm. 2, p. 315–320. https://doi.org/10.2337/db21-0688.
Impacto


Logo de Web of Science    citaciones en Web of Science

Logo de Scopus    citaciones en Scopus

Logo de Google Académico  Google Académico
Compartir
Exportar a Mendeley
Metadatos
Mostrar el registro completo del ítem
Resumen
To evaluate the effect of liraglutide, a glucagon-like peptide 1 receptor agonist, on pulmonary function and serum levels of surfactant protein D (SP-D) in type 2 diabetes. A double-blind, randomized, crossover, placebo-controlled clinical trial comprising 76 patients with a baseline forced expiratory volume in 1 s <90% of that predicted. Liraglutide was administered for 7 weeks (2 weeks of titration plus 5 weeks at 1.8 mg daily). This short duration was intentional to minimize weight loss as a potential confounding factor. Serum level of SP-D was used as a biomarker of alveolar-capillary barrier integrity. Liraglutide exerted a positive impact on forced vital capacity (FVC) in comparison with placebo (ΔFVC 5.2% of predicted [from 0.8 to 9.6]; P = 0.009). No differences in the other pulmonary variables were observed. Participants under liraglutide treatment also experienced a decrease in serum SP-D (P = 0.038). The absolute change in FVC correlated with final serum SP-D in participants receiving liraglutide (r = −0.313, P = 0.036). Stepwise multivariate regression analysis showed that final serum SP-D independently predicted changes in FVC. In conclusion, liraglutide increased FVC in patients with type 2 diabetes. This effect was associated with a significant decrease of circulating SP-D, thus pointing to a beneficial effect in the alveolar-capillary function.
URI
http://hdl.handle.net/10459.1/73145
DOI
https://doi.org/10.2337/db21-0688
Es parte de
Diabetes 2022, vol. 71, núm. 2, p. 315–320
Proyectos de investigación europeos
Colecciones
  • Articles publicats (Medicina) [513]
  • Articles publicats (IRBLleida) [1167]

Contacto | Sugerencias | Aviso legal
© 2023 BiD. Universitat de Lleida
Metadatos sujetos a 
 

 

Explorar

Todo el repositorioComunidades y coleccionesPor fecha de publicaciónAutoresTítulosMateriasEsta colecciónPor fecha de publicaciónAutoresTítulosMaterias

Estadísticas

Ver Estadísticas de uso

De interés

Política institucional d'accés obertDiposita les teves publicacionsDiposita dades de recercaSuport a la recerca

Contacto | Sugerencias | Aviso legal
© 2023 BiD. Universitat de Lleida
Metadatos sujetos a